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Abstract 
PURPOSE: To design bioadhesive Gantrez AN (poly[methyl vinyl ether-co-maleic 
anhydride], PVM/MA) nanoparticles (NP) coated with Vitamin B12 (Vit B12), and 
investigate their application in oral antigen delivery.  
METHODS: The association of Vit B12 to Gantrez AN nanoparticles was performed by 
the direct attachment of reactive Vit B12 to the surface of the nanoparticles (NPB), or 
linking to the copolymer chains in dimethylformamide prior to NP formation (NPB-
DMF). Nanoparticles were characterized by measuring the size, zeta potential, Vit B12 
association efficacy, and stability of Vit B12 on the surface of the nanoparticles. In vivo 
bioadhesion study was performed by the oral administration of fluorescently-labeled 
nanoparticle formulations to rats. Both systemic and mucosal immune responses were 
evaluated after oral and subcutaneous immunization with ovalbumin (OVA) containing 
Vit B12-coated nanoparticles.   
RESULTS: The Vit B12 nanoparticles displayed homogenous size distribution with a 
mean diameter of about 200 nm and a negative surface charge. The association 
efficiency of Vit B12 to NPB-DMF formulation was about two times higher than to the 
NPB, showing also a higher surface stability of Vit B12. The bioadhesion study 
demonstrated that NPB-DMF had an important tropism to the distal portions of the gut, 
which was about 2 and 3.5 times higher than the tropism observed for NPB and control 
NP, respectively (P< 0.05). Oral administration of OVA-NPB-DMF induced also 
stronger and more balanced serum anti-OVA titers of IgG2a (Th1) and IgG1 (Th2) 
compared to control OVA-NP. In addition, oral immunization with OVA-NPB-DMF 
induced a higher mucosal IgA response than subcutaneous administration. 
CONCLUSIONS: These results indicate the benefits of bioadhesive Vit B12-coated 
nanoparticles in oral antigen delivery eliciting systemic and mucosal immune response.  
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Introduction 
Vitamin B12 (cobalamin) has its own intestinal uptake pathway by which it can be 
transported to the systemic circulation. By this mechanism, a molecule of intrinsic 
factor (IF), secreted by the parietal cells in the stomach, interacts and binds to one 
molecule of free vitamin B12. The resulting complex [vitamin B12-IF] moves down the 
gastrointestinal tract until it reaches the ileum. In this region, the complex is recognized 
by the intrinsic factor specific receptors (IF-CR) which are located on the surface of the 
ileal epithelial cells. Then, this complex is internalized by receptor-mediated 
endocytosis. Vitamin B12 is subsequently transported to the systemic circulation and 
complexed with cobalamin-binding protein [Transcobalamin II (TCII)] (1, 2). This 
specific of vitamin B12 uptake system has been explored in the last years to enhance the 
oral delivery of poorly available therapeutic molecules including,  granulocyte colony 
stimulating factor, erythropoietin, and luteinizing hormone-releasing hormone (3-5). 
However, in spite of the numerous advances for the oral delivery of small peptides and 
proteins, some disadvantages have limited the efficiency of this strategy. The directly 
linked macromolecular drugs to vitamin B12 are susceptible to the degradation within 
the gastrointestinal tract. In addition, according to the limited uptake capacity of vitamin 
B12 (2.4 µg/day for adult) (6), the amount of the therapeutic molecule that can be 
delivered as conjugate is limited. An attractive solution to overcome theses problems 
would be the incorporation of drug in nanoparticles coated with vitamin B12. This can 
offer both high loading capacity of the therapeutic molecules and the protection against 
the aggressive gut conditions (pH and enzymatic degradation).  
Studies involving vitamin B12-nanoparticles conjugates have been carried out in vitro 
using Caco-2 cells. They have clearly demonstrated the effective cellular uptake of 
nanoparticles (7) or polymeric micelles containing cyclosporine A coated with vitamin 
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B12 (8). Recently, in vivo results indicated the beneficial use of vitamin B12-coated 
dextran nanoparticles for the oral delivery of insulin (9). However, to date, no published 
studies have been reported on the application of nanoparticles coated with vitamin B12 
derivatives in the mucosal immunization.  
Oral antigen delivery using nanoparticles is being considered as a promising 
strategy for oral vaccination. Orally delivered vaccines can induce high levels of 
mucosal immune response and, thus, protect the host against many pathogens that use 
the mucosal route to invade the body (10, 11). Unfortunately, oral immunization using 
conventional antigen-loaded nanoparticles does not generally elicit a sufficient systemic 
immune response compared to the parenteral routes, and consequently, high and 
multiple oral doses are required (12). This fact is related to the low capacity of 
conventional antigen-loaded nanoparticles to target lymphoid tissues within the gut after 
an oral immunization. The association between antigen-loaded nanoparticles and 
specific ligands (i.e., lectins) may enhance this targeting, resulting in a successful 
antigen delivery to the mucosal surfaces and the induction of the immune response (13, 
14).   
Consequently, our work strategy was to explore the beneficial use of vitamin B12 
as nanoparticles’ targeted ligand to achieve specific bioadhesive profiles within the gut. 
Thus, the main tasks were to optimize the preparation of vitamin B12-coated Gantrez 
AN nanoparticles, and to investigate the in vivo bioadhesive capacity after their oral 
administration to laboratory animals. In addition, the potential immunoadjuvant 
capacity of vitamin B12 nanoparticles was investigated using ovalbumin as standard 
antigen model.   
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Materials and Methods 
Chemicals 
Poly(methyl vinyl ether-co-maleic anhydride) (PVM-MA) Gantrez® AN 119 was 
supplied by ISP (Barcelona, Spain). Reactive vitamin B12-5’OCONH[CH2]6-NH2 was 
kindly gifted by Access Pharmaceuticals Australia (Chatswood, Australia). Rhodamine 
B isothiocyanate (RBITC), 1,3-diaminopropane, ovalbumin (OVA, Grad V), and 
protease inhibitor cocktail  [(4-(2 aminoethyl) benzenesulfonyl fluoride, trans-
epoxysuccinyl-leucyl-amido (4 guanidino) butane (E-64), bestatin, leupeptin, aprotinin, 
and sodium EDTA] were purchased from Sigma (Madrid, Spain). Peroxidase 
conjugated antibodies for IgG1, IgG2a and IgA were supplied by Nordic Immunology 
Labs (Via Cultek S.L, Madrid, Spain). All other reagents were of an analytical grade 
and supplied by Merck (Darmstadt, Germany). 
 
Preparation of Vit B12-Gantrez AN nanoparticle conjugates 
The association between Gantrez AN nanoparticles and reactive vitamin B12 was 
performed by two optimized methods (Figure 1, A and B).   
In method A, Gantrez AN nanoparticles were prepared using a solvent 
displacement method (15). In brief, 100 mg of PVM/MA copolymer were dissolved in 5 
mL acetone, after which the nanoparticles were formed by the addition of 10 mL 
absolute ethanol under magnetic stirring. The organic polymer solution was mixed with 
200 µL deionized water containing 0.5 mg reactive vitamin B12 and magnetically stirred 
for 1 h at RT. Then, 3 mL of deionized water were added, and the organic solvents 
eliminated under reduced pressure (Büchi Rotavapor R-144, Switzerland). The resulting 
nanoparticles were cross-linked for 5 min by the addition of 100 µL of 1,3-
diaminopropane (1,3-DP, 1% w/v) and pelleted by centrifugation at 27,000 x g for 20 
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min (Sigma 3K30, Germany). The supernatant was collected for quantifying the 
unbound vitamin B12. 
For in vivo bioadhesion studies, the centrifuged nanoparticles were fluorescently 
labelled by incubation with 1.25 mg RBITC for 5 minutes at room temperature under 
magnetic stirring after which, the suspension was pelleted again. Both RBITC- loaded 
and non-loaded nanoparticles were lyophilized using sucrose 5% as cryoprotector for  
48 h  in VIRTIS GENESIS freeze drier (Virtis, New York, USA).   
In method B, Vit B12-Gantrez AN nanoparticle conjugates were prepared by the 
reaction between 0.25 mg of reactive vitamin B12 and 100 mg Gantrez AN copolymer in 
12.5 mL dimethylformamide (DMF), under magnetic stirring for 48 h at RT. Then, the 
organic solvent was removed under reduced pressure at 60 ºC for 2-3 h. The formed thin 
film was dissolved in 5 mL acetone, and the nanoparticles were formed and processed 
as described in method A.    
 
Characterization of vitamin B12-Gantrez AN nanoparticle conjugates 
The particle size and zeta potential of nanoparticles were analysed by photon correlation 
spectroscopy (PCS) and electrophoretic laser Doppler anemometry, respectively, using 
a zetamaster analyser system (Malvern Instruments, Malver, UK). The morphology of 
the nanoparticles was observed by scanning electron microscopy in a Zeiss DSM940 
digital scanning electron microscope (Oberkochen, Germany) 
The amount of nanoparticles formed from the original Gantrez AN copolymer (% 
yield) was determined by gravimetry (16). The amount of vitamin B12 bound to the 
surface of the nanoparticles was estimated from the Vit B12 concentration difference 
(colorimetric assay,  540 nm) measured in the supernatant before nanoparticle 
incubation and after the first centrifugation step. The extent of RBITC loading onto the 
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nanoparticles was similarly estimated from the RBITC concentration difference 
measured before nanoparticle incubation and after the second centrifugation step of the 
nanoparticles. 
 
In vitro release of vitamin B12 from nanoparticles 
The stability of the linked vitamin B12 to Gantrez AN nanoparticles was considered to 
be a critical factor for the planned in vivo study and was, therefore, used to select the 
appropriate nanoparticles formulation; indeed, the presence of unbound vitamin B12 can 
exert an auto-inhibitory effect on the binding capacity of Vit B12-Gantrez AN 
nanoparticles to the mucosal cells. Therefore, 10 mg Vit B12-Gantrez AN nanoparticles 
were incubated in 1 mL simulated gastric fluid [SGF (USP XXVIII): pH 1.2, pepsin 
0.32% w/v] for 1 h at 37 ± 1 ºC. Then, the nanoparticles were collected by using 
dialysis tubes (Vivaspin® 100,000 MWCO; VIVASPIN, Hannover, Germany). The 
nanoparticles were then re-incubated in 1 mL of simulated intestinal fluid [SIF (USP 
XXVIII): pH 7.5, pancreatin 1% w/v] for different time periods until 24 h at 37 ± 1 ºC. 
The nanoparticles were collected by dialysis, as described above, after each incubation 
time point. The concentration of free vitamin B12 in all of the collected dialysates was 
determined by colorimetry at 540 nm.    
 
In vivo bioadhesion study 
The bioadhesion studies were carried out using a protocol described previously (16), in 
compliance with the regulations of the European legislation on animal experiments 
(86/609/EU). Briefly, an aqueous suspension containing 10 mg nanoparticles loaded 
with RBITC (approximately 45 mg particles/ kg body weight) was administered  by the 
oral gavages using 16G X 3" (76.2 mm) feeding needle (Proper and Sons, inc., 
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N.Y, U.S.A) to male Wistar rats fasted overnight (average weight 225 g; Harlan, 
Spain). The animals were sacrificed by cervical dislocation at 0.5, 1, 3 and 8 h post 
administration. The abdominal cavity was opened, and the gastrointestinal tract was 
removed. Then, the gut was divided into six anatomical regions: stomach (Sto), intestine 
(I1, I2, I3 and I4) and caecum (Ce). Each mucosa segment was opened lengthwise, 
rinsed with PBS and digested with 3 M NaOH for 24 h. RBITC was extracted from the 
digested samples by addition of 2 mL methanol, vortexed for 1 min and centrifuged at 
2,000 x g for 10 min. Aliquots (1 mL) of the obtained supernatants were diluted with 
water (3 mL) and assayed for RBITC content by spectrofluorimetry at ex 540 nm and 
em 580 nm (GENios, TECAN, Austria) to estimate the fraction of adhered 
nanoparticles on the mucosa. Standard curves were prepared by addition of RBITC 
solutions in 3 M NaOH (0.5-10 µg/mL) to control tissue segments following the same 
steps of extraction (r = 0.996). 
In order to study the kinetic parameters of bioadhesion, the total fraction of 
adhered nanoparticles in the whole gastrointestinal tract was plotted versus time. From 
these curves, the bioadhesion parameters Qmax, AUCadh, Tmax, MRTadh and Kadh were 
estimated from 0 to 8 h post administration as described previously (16) and calculated 
using WinNonlin 1.5 software (Pharsight Corporation, USA). Qmax represents the 
maximal adhered quantity. AUCadh is the area under the curve described for the total 
adhered nanoparticles versus time. Tmax was defined as the time at which maximal 
adhesion in gastrointestinal tract was obtained. MRTadh indicates the mean residence 
time of adhering nanoparticles, and Kadh the elimination rate of total adhering 
nanoparticles. 
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Preparation of OVA-loaded Vit B12-Gantrez nanoparticles  
To study the adjuvant capacity of Vit B12-Gantrez AN nanoparticles, the model antigen 
ovalbumin was loaded into the nanoparticle formulations. As the bioadhesion data 
suggested a benefit of NPB-DMF over NPB, OVA was loaded into the Vit B12-NBP-
DMF nanoparticles according to method B (Figure 1). Briefly, 5 mg OVA were 
sonicated in 5 mL acetone containing 100 mg Gantrez AN-vitamin B12 conjugate. This 
organic dispersoin was magnetically stirred for 1 h at room temperature. The copolymer 
was desolvated by the addition of 10 mL of absolute ethanol and then 3 mL of 
deionized water. The organic solvents were eliminated under reduced pressure (Büchi 
R-144, Switzerland), and the resulting aqueous nanosuspension was cross-linked with 
1,3-DP and pelleted by centrifugation at 27,000 x g for 20 min. The supernatant was 
used to quantify the unbounded vitamin B12. Finally, OVA-NPB-DMF nanoparticle 
dispersion was lyophilized, as described above. Control nanoparticles (OVA-NP) were 
prepared by the same way, but without the use of vitamin B12. 
 
Characterization of OVA-loaded Vit B12-nanoparticles 
The size and zeta potential of the nanoparticles as well as the amount of vitamin B12 
associated to OVA-NPB-DMF were determined as described above. The amount of 
OVA associated to the OVA-NPB-DMF nanoparticles was determined by SDS-PAGE. 
Typically, 5 mg OVA-NPB-DMF nanoparticles were dissolved in 2 mL DMF/acetone 
(1:1, v/v) and then kept at -20 ºC for 24 h. Samples were centrifuged at 10,000 x g for 
15 min, and the precipitate was washed with cold acetone and centrifuged again. The 
amount of OVA was estimated from the average band density of the samples in the 
SDS-PAGE using Micro Image® software (Version 4.0; Olympus Optical, Hamburg, 
Germany); an OVA standard curve was established in the range of 2.5-0.25 µg/band. 
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Immunization protocol 
Animal study protocols were applied in compliance with the regulations of the 
responsible committee of the University of Navarra in line with the European legislation 
on animalexperiments (86/609/EU). Female BALB/c mice of average weight of 20 ± 
1g, supplied by Harlan (Barcelona, Spain), were divided into 6 groups of 10 mice. Mice 
were fasted overnight, with free access to water. The formulations were administered as 
single OVA doses by either oral (100 µg OVA) or subcutaneous (20 µg OVA) route. In 
the oral groups (3 groups, n=10), animals were fed by oral gavage of 200 µL PBS 
containing OVA-NPB-DMF nanoparticles or OVA-NP (control nanoparticles), or OVA 
in solution. In the subcutaneous groups (3 groups, n=10), the animals were injected with 
50 µL PBS containing OVA-NPB-DMF nanoparticles, OVA-NP, or OVA in solution. 
After 2 h post administration, the animals were allowed unrestricted access to water and 
food.   
 
Sample collection 
Blood samples were collected from the retroorbital plexus on 0, 1, 2, 4 and 6 weeks post 
administration. The samples were centrifuged (10,000 x g, 10 min), the sera pooled for 
each group (10 mice), diluted 1:10 with PBS and conserved at -80 ºC untill analysis.  
Faecal samples were collected and analysed as described previously (17). Pooled fresh 
pelleted faeces from each group of mice were put into microtubes on 0, 1, 2, 4, 6 weeks 
post administration and weighed. Non-fatty milk (3%) in phosphate-buffered saline was 
added at 1 mL/100 mg faecal pellets. The pellets were vortexed for 5 min at room 
temperature. Then, the tubes were centrifuged at 10,000 x g for 10 min, and the 
supernatants transferred into tubes containing 10 µL of protease inhibitor cocktail. 
Finally, pooled samples were storedd at -80 °C until analysis. 
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ELISA assay 
Serum anti-OVA IgG1 and IgG2a   
Anti-OVA serum antibodies (IgG1 and IgG2a) were assayed by ELISA using 96 
microtiter plates (Thermo LabSystems, Vantaa, Finland). Wells were coated with OVA 
(100 L per well) in a solution of 10 g/mL of OVA in 0.05 M sodium carbonate–
bicarbonate buffer (pH 9.6) at 4 °C for 24 h. Plates were washed 3 times with PBS 
containing 0.05% Tween 20 (PBS-T) using an ELISA plate washer (Thermo 
Labsystems, Vantaa, Finlandia). Then, wells were incubated with 200 µL of 1% BSA in 
PBS-T for 1 h at room temperature. After washing as described above, serum samples 
(100 µL) were added in twofold serial dilutions in PBS-T starting with 1:40 initial 
dilution, and incubated at 37 ºC for 4 h. The washed wells were incubated for 2 h at 37 
ºC with 100 µL of anti-IgG1 and anti-IgG2a peroxidase-conjugated antibodies 
(GAM/IgG1/PO and GAM/IgG2a/PO) used in dilution of 1:1000 in PBS-T. For color 
development, the substrate-chromogen used was H2O2-ABTS (3-ethylbenzthiazoline-6-
sulfonic acid). The absorbance (Abs) was determined at 405 nm (iEMS Reader MF de 
Labsystems, Vantaa, Finlandia), and the end-point titer determined as the sample 
dilution giving a mean Abs  0.2 above that measured for untreated mice sera.   
For semi-quantitative comparison between immune responses induced by the different 
nanoparticle formulations, the areas under the curves of the antibody response profiles 
(AUCth1(IgG2a) and AUCth2(IgG1)) were calculated for the period of 0 - 6 weeks post 
immunization using the WinNonline 1.5 software (Pharsight Corp, USA),  as described 
previously (16).  
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Faecal anti-OVA IgA  
After the washing step of OVA-coated plates, as described above, the plates were 
blocked with 200 µL 3% non-fatty milk in PBS-T for 1 h at room temperature. Faecal 
extract samples of 100 µL were added starting with undiluted samples and followed by 
twofold serial dilutions up to 1:64 in PBS-T; the plates were incubated at 37 ºC for 4 h. 
After washing the wells, 1:1000 dilutions of anti-IgA peroxidase conjugated antibody 
(GAM/IgA/PO) were added. The detection step and the end titers were determined as 
described above. 
 
Statistical methods  
The bioadhesion data and the physico-chemical characteristics were compared using the 
nonparametric Mann-Whitney U-test and Student t-test, respectively. P values of < 0.05 
were considered significant. All calculations were performed using SPSS® statistical 
software program (SPSS® 10, Microsoft, USA). 
 
  
  
 14 
Results 
Characteristics of nanoparticle formulations 
Vit B12-nanoparticle conjugates were prepared by two different methods. In method A, 
vitamin B12 was bound to the surface of previously prepared nanoparticles. In method 
B, a Vit B12-Gantrez AN conjugate was first prepared, which was subsequently used to 
prepare the nanoparticles. All nanoparticle formulations were prepared with similar 
yields (about 80%) and showed homogenous size distributions with a mean diameter of 
about 200 nm (Table 1, Figure 2). Both types of Vit B12-nanoparticles (NPB and NPB-
DMF; see Figure 1) displayed a similar negative zeta potential, which differed 
significantly from that measured with control nanoparticles (P< 0.05) (Table 1). The 
content of vitamin B12 was higher in the NPB-DMF nanoparticles than in the NPB 
nanoparticles (P< 0.05). In addition, the association efficiency of vitamin B12 to the 
nanoparticles prepared by method B was two times higher than that obtained with the 
nanoparticles prepared by method A (Table 1). Finally, the amount of loaded RBITC 
was similar, i.e., appro.x 13 µg/mg nanoparticles, for all the nanoparticle formulations.  
 
In vitro release of vitamin B12 from the nanoparticles 
Figure 3 illustrates the release of vitamin B12 from nanoparticles after their subsequent 
incubation in simulated gastric fluid (SGF) and intestinal fluid (SIF). After 1 h 
incubation in SGF (pH 1.2), NPB produced a significant release of vitamin B12, which 
was about 30% of the total amount of associated vitamin B12. When this formulation 
was subsequently incubated in SIF (pH 7.5), the release of vitamin B12 continued in a 
more sustained way and reached approx. 50% of the total dose within 24 h. On the 
contrary, less than 3% of vitamin B12 were released from NPB-DMF after their 
incubation in SGF (1 h) and SIF (23 h). 
  
  
 15 
In vivo bioadhesion study 
Figure 4 shows the distribution of the adhered nanoparticles throughout the different 
sections of the GI tract after a single oral administration of 10 mg RBITC-loaded 
nanoparticles. Thirty minutes after administration, the Vit B12-nanoparticles (NPB, 
NPB-DMF) and control nanoparticles (NP) displayed a similar capacity to adhere to the 
gut, with a preferential distribution in the stomach and upper regions of the small 
intestine (Figure 4 a,b,c). Interestingly, at 3 h post administration, both Vit B12-
nanoparticle formulations displayed a higher tropism for the distal part of the gut (I3 & 
I4 portions) than the control nanoparticles (NP). Furthermore, this tropism was 2 and 
3.5-times higher with the NPB-DMF nanoparticles than with the NPB and control 
nanoparticles (NP), respectively. 
 
Analysis of the bioadhesion kinetics (Figure 5) revealed that control nanoparticles 
achieved their maximal gut adhesion within the first 30 min, whereas the Vit B12-
nanoparticle formulations required 3 h to reach Tmax (Table 2). On the other hand, both 
the maximum amount (Qmax) and total amount (AUCadh) of adhered nanoparticles were 
significantly higher for the NPB-DMF nanoparticles than for the NPB or control 
nanoparticles (p< 0.01). The mean residence time of the adhered nanoparticle fraction 
(MTRadh) was similar, i.e., approx. 3.5 h, for all nanoparticle formulations. Finally, the 
elimination constant (Kadh) for the adhered fraction of nanoparticles was significantly 
higher for the NPB-DMF nanoparticles than for the other formulations (Table 2).     
 
Characteristics of OVA-loaded Vit B12 nanoparticles 
For the immunization studies, the model antigen OVA was encapsulated in the Vit B12-
nanoparticle formulation NPB-DMF and control nanoparticles free of vitamin B12 (NP). 
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The OVA-NPB-DMF nanoparticles displayed a slightly lower mean diameter (230 nm) 
than the control OVA-loaded nanoparticles (OVA-NP, 270 nm). The amount of vitamin 
B12 associated to OVA-NPB-DMF nanoparticles was approx. 2.4 µg/mg NP.  The 
amount of  OVA loaded in the nanoparticles was approx. 12 µg OVA/mg NP and 
similar for both the OVA-NPB-DMF nanoparticles and OVA-NP.  
 
OVA-specific serum antibody response 
Figure 6 shows OVA-specific IgG2a and IgG1 serum titers measured after oral gavage 
or subcutaneous (s.c.) administration of a single dose of OVA-loaded Vit B12-
nanoparticles (OVA-NPB-DMF), OVA-loaded control nanoparticles free of vitamin B12 
(OVA-NP) and free OVA. After both the oral and s.c. administrations, both 
nanoparticle formulations enhanced the serum antibody responses (IgG2a, IgG1) 
compared to free antigen. Upon s.c. immunization, the IgG2a titers (mirroring a Th1 
response) elicited by the OVA-NPB-DMF nanoparticles were at least two times higher 
than those elicited by the OVA-NP (see AUC-values, Figure 6 a,b), although both 
OVA-loaded nanoparticle formulations (OVA-NPB-DMF and OVA-NP) induced 
similar IgG1 titers (mirroring a Th2 response). 
 
Oral immunization with the control OVA-NP showed a predominant IgG1 response 
(AUCIgG1 was seven times higher than AUCIgG2a, Figure 6 c,d). In contrast, oral 
immunization with OVA-NPB-DMF elicited stronger and more balanced Th1/Th2 
responses as compared to the control OVA-NP. The sum of both the AUCIgG1 and 
AUCIgG2a for OVA-NPB-DMF was about  three times higher than that calculated for 
OVA-NP (Figure 6 c,d).  
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Anti-OVA specific intestinal IgA 
Figure 7 illustrates the faecal anti-OVA IgA response after subcutaneous and oral 
immunization of the different formulations tested. Both nanoparticle formulations 
elicited higher levels of intestinal IgA compared to free OVA when administered by 
either the s.c. or oral route. Interestingly, the oral administration of OVA-NPB-DMF 
elicited higher levels of intestinal secretory IgA compared to the s.c. administration. 
This mucosal immune response (IgA) was about four log2-titers (approx. 100-fold) 
higher than that elicited by OVA-NP.  
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Discussion 
The first objective of this work was to optimize the preparation of Vit B12-Gantrez AN 
nanoparticle conjugates. For this purpose, the association of vitamin B12 to the 
nanoparticles was done by applying two different  methods, where vitamin B12 was 
either directly attached to the surface of the nanoparticles (NPB, method A), or linked to 
the copolymer chains prior to nanoparticle formation (NPB-DMF, method B). Both Vit 
B12- nanoparticle types displayed a homogenous size distribution with mean diameter of 
about 200 nm, and a less negative surface charge compared to control nanoparticles 
(NP). The high density of negative surface charge of the control NP is due to the 
exposure of hydrolyzed carboxylic groups of Gantrez AN copolymer. The attachment of 
primary amine-containing molecules such as 1,3-diaminopropane, lectins or proteins to 
the surface of Gantrez nanoparticles decreases their negative surface charge (15, 18). 
This may explain the significant decrease in the negative surface charge of both types of 
vitamin B12 nanoparticles when reactive vitamin B12-NH2 was directly attached to 
Gantrez nanoparticles or linked to the copolymer. 
    
During the optimization of the nanoparticle preparation methods (A and B) we noticed 
that method B (NPB-DMF; 250 µg vitamin B12 per 100 mg Gantrez AN in DMF) 
required only half of the amount of reactive vitamin B12 to yield a loading of approx. 
2.4 µg/mg NP (Table 1) than method A (NPB; 500 µg vitamin B12 per 100 mg Gantrez 
AN nanoparticles, in an aqueous dispersion). This result correlated with the twofold 
higher association efficiency of vitamin B12 to the NPB-DMF as compared to the NPB 
nanoparticles.  
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The physical stability of association of vitamin B12 and Gantrez AN nanoparticles was 
considered as a critical factor for the in vivo experiments, since free vitamin B12 was 
expected to exert an auto-inhibitory effect on the mucosal affinity of Vit B12-Gantrez 
AN nanoparticles after their oral administration. Therefore, the release of vitamin B12 
was studied upon subsequent incubation of the nanoparticles in simulated gut fluids. 
The release of vitamin B12 form both types of nanoparticles showed that the vitamin B12 
remained more strongly associated to NPB-DMF than to the NPB nanoparticles (Figure 
3).  
 
The differences in vitamin B12 association efficiency stability between the two 
nanoparticle formulations may depend on the reaction conditions under which vitamin 
B12 was coupled to Gantrez AN copolymer (NPB-DMF) or linked to the surface of the 
nanoparticles (NPB). The expected formation of stable amide bonds between the 
primary amine group of vitamin B12-5’OCONH[CH2]6-NH2 and the anhydride group of 
Gantrez AN nanoparticles (19) may have been hampered in the presence of water used 
for this reaction with the NPB. Indeed, the high hydrolysis rate of the anhydride groups 
of the poly(methyl vinyl ether-co-maleic anhydride) may have produced carboxylic 
groups that formed less stable charged ionic or hydrogen bonds with the reactive 
vitamin B12 derivative. Conversely, the coupling of vitamin B12 to the copolymer (NPB-
DMF) in the absence of water must have yielded a high fraction of stable covalent 
bonds between vitamin B12 and the copolymer. These observations are in agreement 
with previous results obtained for the pegylation of Gantrez AN nanoparticles (20), 
where a threefold higher pegylation of Gantrez nanoparticles was achieved when 
polyethylene glycol was reacted with Gantrez in an organic phase prior to nanoparticle 
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formation as compared to the coating of freshly prepared nanoparticles with 
polyethylene glycol. 
 
The in vivo bioadhesive capacity of Vit B12-nanoparticles was investigated after oral 
administration of fluorescently labelled NPB and NPB-DMF to fasted rats. The adhered 
fractions of nanoparticles were mainly found in the stomach and upper regions of the 
small intestine at 30 min post administration (Figure 4 a,b,c). At 3 hours post 
administration, both Vit B12-nanoparticle formulations showed an important tropism to 
the distal portions of the gut (I3 & I4 regions). The tropism of the NPB-DMF 
nanoparticles represented about 28% of the given dose and was about 2 and 3.5 times 
more than the tropism observed for the NPB and control nanoparticles, respectively (P< 
0.05). From a physiological point of view, the ileum is the region of the gastrointestinal 
tract where the Vit B12-intrinsic factor (IF) complex is transported (1). Therefore, these 
results appear to demonstrate the biological property of vitamin B12 on the surface of 
the nanoparticles (NPB-DMF) to bind effectively to the IF, with subsequent binding of 
the IF-Vit B12- nanoparticles to the IF receptors of the mucosal cells.  
 
Interestingly, we noted a good agreement between the vitamin B12 release (Figure 3) 
and the bioadhesive capacity (ileal tropism) of the two types of vitamin B12 
nanoparticles (Figure 4). The twofold enhanced ileal tropism of NPB-DMF 
nanoparticles over that of the NPB may be related to the strong association of vitamin 
B12 to the NPB-DMF nanoparticles (Figure 3), whereas the important release of vitamin 
B12 from the NPB (Figure 3) probably exerted an auto-inhibitory effect on the ileal 
tropism of the nanoparticles. Such competing effect between orally administered free 
vitamin B12 and vitamin B12-peptide conjugates, which negatively affected the process 
  
  
 21 
of uptake and transport to the circulation of the conjugate, has been described in the 
literature (21). 
 
NPB-DMF and NPB nanoparticles reached the maximal gut adhesion at 3 h post 
administration (Figures 4 and 5, Table 2), whereas the control nanoparticles achieved 
their maximal bioadhesion already at 0.5 h post administration. These results indicate 
that control nanoparticles without vitamin B12 on their surface distribute quickly in the 
stomach and upper ileal segments, which is mediated by non-specific bioadhesive 
interactions between the Gantrez AN copolymer and the mucosal surfaces. However, 
the presence of vitamin B12 on the surface of the nanoparticles prolongs substantially 
the time needed to reach the maximal gut adhesion, which we ascribe to specific 
bioadhesive interactions between the vitamin B12 and the IF-receptor of the mucosal 
cells. 
  
Arbós and co-workers demonstrated that surface modifications of conventional Gantrez 
AN nanoparticles with lectins can delay the time of maximal bioadhesion of control 
nanoparticles from 0.5 h to 1 h post oral administration (16).  Similarly, oral 
administration of vitamin B12-conjugates with peptides to rats yielded the highest tissue 
concentration in the small intestine after 4 hours post oral administration (21). The time 
of 4 hours agrees well with our data suggesting that similar bioadhesive kinetics 
determined the fate of both the vitamin B12-peptide and vitamin B12-nanoparticle 
conjugates in the same animal model. 
 
Finally, to investigate the adjuvant capacity of Vit B12-nanoparticles as antigen delivery 
system, the antibody immune response was studied in BALB/c mice. Both s.c. and oral 
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administration of the OVA-loaded nanoparticle formulations elicited a stronger serum 
antibody response than free OVA. In the s.c. immunization, the OVA-NP induced a 
considerable IgG1 (Th2) response, whereas the OVA-loaded Vit B12-nanoparticles 
(OVA-NPB-DMF) induced higher IgG2a levels (Th1 response) than OVA-NP. The 
IgG2a response may be related to effective uptake of Vit B12-nanoparticles by antigen 
presenting cells, although this hypothesis requires further investigation. The intragastric 
inoculation of the OVA-NPB-DMF formulation induced also stronger and more 
balanced serum titers of IgG2a (Th1) and IgG1 (Th2) compared to the OVA-NP, which 
induced a typical Th2 response (Figure 6 c,d). For semi-quantitative analysis, the 
cumulated areas under the curve of the antibody response profiles (AUCIgG2a + 
AUCIgG1) were found to be approx. three times larger for OVA-NP-DMF than for OVA-
NP. This emphasized again the strong adjuvant capacity of Vit B12-nanoparticles when 
loaded with ovalbumin. 
 
These results clearly indicated the capacity of Vit B12-nanoparticles to enhance a Th1 
response after both s.c. and oral immunization of BALB/c mice, which have a genetic 
tendency towards a Th2 response (22). This Th1 response enhancement may be related 
to the high ileal tropism of Vit B12-nanoparticles, where Peyer’s patches with a high 
density of antigen presenting cells are found to be concentrated. In contrast, control 
nanoparticles did not show ileal tropism and elicited only a week Th2 type immune 
response.  These results agree with those reported on the delivery of OVA-loaded 
microbeads to lower intestine region, where they enhanced a Th1 response (23). Finally, 
the oral immunization with OVA-NPB-DMF induced a higher mucosal IgA response 
than the s.c. administration. In summary, these results support further studies in order to 
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apply Vit B12-Gantrez AN nanoparticles in protective mucosal vaccination or 
immunotherapy purposes.  
 
Conclusions 
The present results demonstrate the adjuvant benefits of vitamin B12 association to 
Gantrez AN nanoparticles for oral antigen delivery. The bioadhesive capacity and ileal 
tropism of the orally administered OVA-loaded and vitamin B12–decorated 
nanoparticles appeared to be instrumental for the effective elicitation of both systemic 
and mucosal immune responses. Further efforts should be focused on exploring the role 
of vitamin B12 in the interaction with immune cells and their potential activation.   
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Table 1. Physicochemical characteristics of the Vit B12-nanoparticles. Data expressed as 
mean ± SD (n=6). 
 Size 
(nm)a 
PDIb Zeta 
potential 
(mV)c 
Yieldd 
(%) 
 
Vit B12 
content 
(µg/mg)e 
Association 
efficiency 
of  vitamin B12 
to NP (%)f 
NP 203 ± 1 0.15 ± 0.04 - 47 ± 1 78 ± 1 - - 
NPB 200 ± 3 0.16 ± 0.03 -24 ± 3* 83 ± 1 2.32 ± 0.07 38 ± 1 
NPB-DMF 198 ± 1 0.09 ± 0.08 -26 ± 2* 79 ± 2 2.45 ± 0.05   77 ± 1* 
NPB and NPB-DMF: Vit B12-nanoparticles prepared by methods A and B  (see Figure 1)  
a Measurement of the nanoparticle size by photon correlation spectroscopy 
b
 Polydispersity index 
c
 Measurement of the zeta potential by electrophoretic laser Doppler anemometry 
d Percentage of nanoparticles formed relative to the initial amount of polymer used  
e Amount of vitamin B12 associated to the nanoparticles expressed in µg /mg NP 
f
 Association efficiency of vitamin B12 to the nanoparticles formulation expressed in percentage relative to 
the initial amounts of materials used 
*P< 0.05; MNPB and NPB-DMF versus control nanoparticles (NP) (Student t-test). 
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Table 2. Bioadhesion kinetic parameters for the tested formulations. Data expressed as 
mean ± SD (n =3) 
 
Qmax (mg) Tmax (h) AUCadh(mg.h) Kadh (h-1) MRTadh (h) 
NP 2.13 ± 0.18 0.5 10.95 ± 0.1 0.13 ± 0.08 3.45 ± 0.32 
NPB 2.17 ± 0.46 3 12.87 ± 2.1 0.11 ± 0.01 3.77 ± 0.14 
NPB-DMF 3.61 ± 0.73** 3 24.41 ± 2.2** 0.22 ± 0.08* 3.53 ± 0.24 
NPB and NPB-DMF: Vit B12-nanoparticles prepared by methods A and B (see figure 1).  
Qmax (mg): Maximal amount of nanoparticles adhering to the intestinal mucosa 
AUCadh (mg.h): Area under the curve of nanoparticles adhering to the intestinal mucosa   
Kadh (h-1): Terminal elimination rate of the adhered fraction of nanoparticles  
MRTadh (h): Mean residence time of the adhered fraction of nanoparticles 
Tmax: The time needed to reach the maximal adhesion 
* P< 0.05, ** P< 0.01 for NPB-DMF versus control nanoparticles NP (Man-Whitney U-test). 
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Legend to figures 
Figure 1. Schematic representation of the methods A and B used for preparing the 
Gantrez AN nanoparticles and associating vitamin B12 to the nanoparticles.  
 
Figure 2. Scanning electron micrographs (SEM) of lyophilized Vit B12-nanoparticles 
(NPB-DMF). 
 
Figure 3. Vitamin B12 release profiles from Vit B12-Gantrez nanoparticles upon their 
subsequent incubation in simulated gastric and intestinal fluids. The nanoparticle 
formulations were: () NPB and () NPB-DMF. Data represented as mean ±SD (n=3).  
 
Figure 4. Distribution of nanoparticles in the gastrointestinal tract of rats after oral 
administration of 10 mg RBITC-loaded nanoparticles. (a) Control nanoparticles (NP); 
(b) Vit B12-NP prepared by method A (NPB); (c) Vit B12-NP prepared by method B 
(NPB-DMF). The x-axis represents the different gut segments of stomach (Sto), 
intestinal sections (I1, I2, I3, I4), and caecum (Ce). The y-axis shows the adhered 
amounts of nanoparticles on the mucosa. The z-axis represents the post administration 
time. Each value is represented by the mean (n=3; SD was less than 20% of the mean).  
 
Figure 5. Kinetics of bioadhesion of Vit B12-nanoparticles throught the whole 
gastrointestinal tract versus time: () NPB, () NPB-DMF,  ()control NP. Each value 
is represented by the mean ± SD (n = 3). **P< 0.01 NPB-DMF vs. NPB and control 
nanoparticles (NP). ×P< 0.05 NP vs. NPB-DMF and NPB.  
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Figure 6. OVA-specific serum IgG2a and IgG1 in BALB/c mice (n =10). The animals 
were immunized on day 0 with a single dose of the formulations containing 20 µg OVA 
for the subcutaneous route (a, b) or 100 µg OVA for the oral route (c, d). The 
formulations were: OVA-NPB-DMF (), OVA-NP (), free OVA (). AUC is the area 
under the curve of the immune response profiles calculated over the time of the 
experiment. 
 
Figure 7. Faecal secretory OVA-specific IgA in BALB/c mice (n =10). The animals 
immunized on day 0 by a single dose of the formulations containing 20 µg OVA for the 
subcutaneous route or 100 µg OVA for the oral route. The formulations were: OVA-
NPB-DMF (), OVA-NP (), free OVA ().  
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Figure 1 
 
 
 
A 
100 mg   Gantrez AN dissolved in 
5 mL acetone 
Addition of 3 mL water, evaporation under reduced pressure, and 
cross-linking by 100 µL 1,3-diaminopropane (1,3-DP)  
Centrifugation at 27,000 x g and then lyophilization using 5% sucrose  
Incubation of the nanoparticles with 200 µL 
aqueous solution contained 0.5 Vit B12 for 1h, at 
RT.  
NPB  
Gantrez AN nanoparticles formation by the addition of 10 mL absolute ethanol  
Incubation of 0.25 mg Vit B12 with 12.5 mL 
dimethylformamide (DMF), containing 100 mg 
Gantrez AN for 48 h, at RT 
Evaporation of DMF under reduced 
pressure for 2-3h, at 60ºC, followed by 
the addition of 5 mL acetone 
  NPB-DMF  
B 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 900 nm 20000x, 5mm, 20KV, 6/4/06, B1203. 
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